Celgene

Among leading biotech and emerging pharmaceutical companies, short sellers moved on BioMarin Pharmaceutical (NASDAQ: BMRN), Celgene (NASDAQ: CELG) and Regeneron Pharmaceuticals (NASDAQ: REGN) the most between the August 30 and September 13 settlement dates. The number of shares sold short in...

Declining short interest in Alexion Pharmaceuticals (NASDAQ: ALXN) and Pharmacyclics (NASDAQ: PCYC) bucked the trend among leading biotech and emerging pharmaceutical companies between the August 15 and August 30 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Biogen...

Among leading biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw significant percentage declines in short interest between the July 31 and August 15 settlement dates. Short sellers also shied away...

Among biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Onyx Pharmaceuticals (NASDAQ: ONXX) and Pharmacyclics (NASDAQ: PCYC) saw the most significant percentage declines in short interest between the June 28 and July 15 settlement dates. Short sellers also shied away from...

Among biotech and emerging pharmaceutical companies, Gilead Sciences (NASDAQ: GILD) and Onyx Pharmaceuticals (NASDAQ: ONXX) saw the most significant rises in short interest between the June 14 and June 28 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena...

Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest between the May 31 and June 14 settlement dates. The number of shares sold short in Onyx Pharmaceuticals (NASDAQ: ONXX), Pharmacyclics (NASDAQ: PCYC) and Regeneron...

Among biotech and emerging pharmaceutical companies, Biogen Idec (NASDAQ: BIIB), saw the most significant rise in short interest between the May 15 and May 31 settlement dates. The number of shares sold short in Amgen (NASDAQ: AMGN), Dendreon (NASDAQ: DNDN), Onyx Pharmaceuticals (NASDAQ: ONXX)...

Among biotech and emerging pharmaceutical companies, Regeneron Pharmaceuticals (NASDAQ: REGN) and Vertex Pharmaceuticals (NASDAQ: VRTX) saw he most significant rise in short interest between the April 30 and May 15 settlement dates. The number of shares sold short in Alexion Pharmaceuticals (...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the latter two weeks of April. The number of shares sold short in Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX) and VIVUS (NASDAQ: VVUS)...

The research team at PropThink, which focuses on emerging growth companies in the health care sector, recently offered a list of bargain biotech stocks worth a look. The stocks that made the list include Endo Health Solutions (NASDAQ: ENDP), Illumina (NASDAQ: ILMN) and Keryx Biopharmaceuticals (...

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD...

Amgen (NYSE: AMGN), shares of which reached a multiyear high Monday, is scheduled to report its first-quarter 2013 results Tuesday, April 23, after the markets close. Investors will be keeping an eye on the impact that a recent German regulatory review of drug prices may have on the company over...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX), Vertex...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of March. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the...

“This is where money goes to die,” has described one sector over the past decade but this year, things are different. That industry is health care and for the first time since 1988, it leads the S&P with a 12 percent gain—the most among the 10 main groups. Specifically, health insurers,...